Related references
Note: Only part of the references are listed.Satin therapy increases lipoprotein(a) levels
Sotirios Tsimikas et al.
EUROPEAN HEART JOURNAL (2020)
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
Francois Mach et al.
EUROPEAN HEART JOURNAL (2020)
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome
Vera A. Bittner et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Lipoprotein(a) Reduction in Persons with Cardiovascular Disease
Sotirios Tsimikas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
From traditional pharmacological towards nucleic acid-based therapies for cardiovascular diseases
Ulf Landmesser et al.
EUROPEAN HEART JOURNAL (2020)
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
Kausik K. Ray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Effect of C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients With High-Risk Vascular Disease A Prespecified Secondary Analysis of the ACCELERATE Trial
Rishi Puri et al.
JAMA CARDIOLOGY (2020)
Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial
Michael Szarek et al.
EUROPEAN HEART JOURNAL (2020)
Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial
Michael Szarek et al.
EUROPEAN HEART JOURNAL (2020)
Lipoprotein(a) and Oxidized Phospholipids Promote Valve Calcification in Patients With Aortic Stenosis
Kang H. Zheng et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Estimation of the Required Lipoprotein(a)-Lowering Therapeutic Effect Size for Reduction in Coronary Heart Disease Outcomes A Mendelian Randomization Analysis
Claudia Lamina et al.
JAMA CARDIOLOGY (2019)
Lipoprotein apheresis for lipoprotein(a) and cardiovascular disease
Patrick M. Moriarty et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2019)
Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk Insights From the FOURIER Trial
Michelle L. O'Donoghue et al.
CIRCULATION (2019)
Lipoprotein(a)-Lowering by 50 mg/dL (105 nmol/L) May Be Needed to Reduce Cardiovascular Disease 20% in Secondary Prevention
Christian M. Madsen et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2019)
Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment
Lotte C. A. Stiekema et al.
EUROPEAN HEART JOURNAL (2019)
Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size
Sotirios Tsimikas et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2018)
Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies A Mendelian Randomization Analysis
Stephen Burgess et al.
JAMA CARDIOLOGY (2018)
Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials
Peter Willeit et al.
LANCET (2018)
Impact of Apolipoprotein(a) Isoform Size on Lipoprotein(a) Lowering in the HPS2-THRIVE Study
Sarah Parish et al.
CIRCULATION-GENOMIC AND PRECISION MEDICINE (2018)
A Test in Context: Lipoprotein(a) Diagnosis, Prognosis, Controversies, and Emerging Therapies
Sotirios Tsimikas
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Rationale and design of MultiSELECt: A European Multicenter Study on the Effect of Lipoprotein(a) Elimination by lipoprotein apheresis on Cardiovascular outcomes
Bernd Hohenstein et al.
ATHEROSCLEROSIS SUPPLEMENTS (2017)
Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans
Mark J. Graham et al.
JOURNAL OF LIPID RESEARCH (2016)
Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization
Eberhard Roeseler et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2016)
Prevalence of Elevated Lp(a) Mass Levels and Patient Thresholds in 532 359 Patients in the United States
Steve Varvel et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2016)
Thematic Review Series: Lipoprotein (a): Coming of Age at Last Lipoprotein apheresis to treat elevated lipoprotein (a)
Elisa Waldmann et al.
JOURNAL OF LIPID RESEARCH (2016)
Thematic Review Series: Lipoprotein (a): Coming of Age at Last Structure, function, and genetics of lipoprotein (a)
Konrad Schmidt et al.
JOURNAL OF LIPID RESEARCH (2016)
Phenotypic Characterization of Genetically Lowered Human Lipoprotein(a) Levels
Connor A. Emdin et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)
Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials
Nicholas J. Viney et al.
LANCET (2016)
Disposition and Pharmacokinetics of a GalNAc3-Conjugated Antisense Oligonucleotide Targeting Human Lipoprotein (a) in Monkeys
Rosie Z. Yu et al.
NUCLEIC ACID THERAPEUTICS (2016)
Disposition and Pharmacology of a GalNAc3-conjugated ASO Targeting Human Lipoprotein (a) in Mice
Rosie Z. Yu et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2016)
Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis
Romain Capoulade et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2015)
Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study
Sotirios Tsimikas et al.
LANCET (2015)
Lomitapide and Mipomersen Two First-in-Class Drugs for Reducing Low-Density Lipoprotein Cholesterol in Patients With Homozygous Familial Hypercholesterolemia
Daniel J. Rader et al.
CIRCULATION (2014)
Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients
Martin J. Landray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Relationship of Apolipoproteins A-1 and B, and Lipoprotein(a) to Cardiovascular Outcomes The AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglyceride and Impact on Global Health Outcomes)
John J. Albers et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Genetic Associations with Valvular Calcification and Aortic Stenosis
George Thanassoulis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Nicotinic acid inhibits hepatic APOA gene expression: studies in humans and in transgenic mice
Indumathi Chennamsetty et al.
JOURNAL OF LIPID RESEARCH (2012)
EFFECT OF MIPOMERSEN ON LIPOPROTEIN(A) IN PATIENTS WITH HYPERCHOLESTEROLEMIA ACROSS FOUR PHASE III STUDIES
Sotirios Tsimikas et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Antisense Oligonucleotide Lowers Plasma Levels of Apolipoprotein (a) and Lipoprotein (a) in Transgenic Mice
Esther Merki et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2011)
Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study
Kåre Berg et al.
CLINICAL GENETICS (2010)
Lp(a) lipoprotein and pre-β1-lipoprotein in patients with coronary heart disease
Kåre Berg et al.
CLINICAL GENETICS (2010)
Effects of Ezetimibe on Remnant-Like Particle Cholesterol, Lipoprotein (a), and Oxidized Low-Density Lipoprotein in Patients with Dyslipidemia
Tsuyoshi Nozue et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2010)
Use of the Thyroid Hormone Analogue Eprotirome in Statin-Treated Dyslipidemia
Paul W. Ladenson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
Robert Clarke et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice
Esther Merki et al.
CIRCULATION (2008)
Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia
Frederick F. Samaha et al.
NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE (2008)
Niacin in cardiovascular prevention: mechanisms, efficacy, and safety
John R. Guyton
CURRENT OPINION IN LIPIDOLOGY (2007)
High-level lipoprotein [a] expression in transgenic mice: evidence for oxidized phospholipids in lipoprotein [a] but not in low density lipoproteins
M Schneider et al.
JOURNAL OF LIPID RESEARCH (2005)
Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause
MG Shlipak et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2000)
Share Paper
